Ruxolitinib
Back to searchMolecule Structure
Scientific Name
Ruxolitinib
Description of the Drug
Ruxolitinib is a kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08877
http://www.drugbank.ca/drugs/DB08877
Brand Name(s)
Jakavi
Company Owner(s)
Incyte Corp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Tyrosine-protein kinase JAK2 | SINGLE PROTEIN | INHIBITOR | CHEMBL2971 |
| Tyrosine-protein kinase JAK1 | SINGLE PROTEIN | INHIBITOR | CHEMBL2835 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL171319 | SCHEMBL16546708 | |
| PharmGKB | PA166123386 | ||
| DrugBank | DB08877 | ||
| PubChem: Thomson Pharma | 81071277 | ||
| PubChem | 25126798 | ||
| LINCS | LSM-1139 | ||
| Nikkaji | J2.740.099J | ||
| PDBe | RXT | ||
| BindingDB | 50355501 | ||
| EPA CompTox Dashboard | DTXSID10240930 | ||
| DrugCentral | 4190 | ||
| Brenda | 39793 | 19116 | |
| ChemicalBook | CB02499581 | ||
| Guide to Pharmacology | 5688 | ||
| rxnorm | JAKAFI | RUXOLITINIB PHOSPHATE | RUXOLITINIB |
| ChEBI | 66919 | ||
| ZINC | ZINC000043207851 |
